{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:25:50Z","timestamp":1775708750490,"version":"3.50.1"},"reference-count":219,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/IMI-MIC\/1683\/2014"],"award-info":[{"award-number":["PTDC\/IMI-MIC\/1683\/2014"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/BTM-SAL\/29786\/2017"],"award-info":[{"award-number":["PTDC\/BTM-SAL\/29786\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The genus Mycobacterium comprises not only the deadliest of bacterial pathogens, Mycobacterium tuberculosis, but several other pathogenic species, including M. avium and M. abscessus. The incidence of infections caused by atypical or nontuberculous mycobacteria (NTM) has been steadily increasing, and is associated with a panoply of diseases, including pulmonary, soft-tissue, or disseminated infections. The treatment for NTM disease is particularly challenging, due to its long duration, to variability in bacterial susceptibility profiles, and to the lack of evidence-based guidelines. Treatment usually consists of a combination of at least three drugs taken from months to years, often leading to severe secondary effects and a high chance of relapse. Therefore, new treatment approaches are clearly needed. In this review, we identify the main limitations of current treatments and discuss different alternatives that have been put forward in recent years, with an emphasis on less conventional therapeutics, such as antimicrobial peptides, bacteriophages, iron chelators, or host-directed therapies. We also review new forms of the use of old drugs, including the repurposing of non-antibacterial molecules and the incorporation of antimicrobials into ionic liquids. We aim to stimulate advancements in testing these therapies in relevant models, in order to provide clinicians and patients with useful new tools with which to treat these devastating diseases.<\/jats:p>","DOI":"10.3390\/antibiotics9010018","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T11:55:07Z","timestamp":1578052507000},"page":"18","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Looking beyond Typical Treatments for Atypical Mycobacteria"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9019-7334","authenticated-orcid":false,"given":"Clara M.","family":"Bento","sequence":"first","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IBMC\u2014Instituto de Biologia Molecular e Celular, Universidade do Porto, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7657-2118","authenticated-orcid":false,"given":"Maria Salom\u00e9","family":"Gomes","sequence":"additional","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IBMC\u2014Instituto de Biologia Molecular e Celular, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"ICBAS\u2014Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6087-1487","authenticated-orcid":false,"given":"T\u00e2nia","family":"Silva","sequence":"additional","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IBMC\u2014Instituto de Biologia Molecular e Celular, Universidade do Porto, 4200-135 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"(1997). Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am. J. Respir. Crit. Care Med., 156, S1\u2013S25.","DOI":"10.1164\/ajrccm.156.2.atsstatement"},{"key":"ref_2","first-page":"107","article-title":"Nontuberculous mycobacteria and associated diseases","volume":"119","author":"Wolinsky","year":"1979","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cowman, S., van Ingen, J., Griffith, D.E., and Loebinger, M.R. (2019). Non-tuberculous mycobacterial pulmonary disease. Eur. Respir. J., 54.","DOI":"10.1183\/13993003.00250-2019"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria: A review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin. Chest Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-0038-1651491","article-title":"Epidemiology of Nontuberculous Mycobacteriosis","volume":"39","author":"Adjemian","year":"2018","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.thorsurg.2018.09.006","article-title":"Nontuberculous Mycobacteria: Epidemiology and the Impact on Pulmonary and Cardiac Disease","volume":"29","author":"Drummond","year":"2019","journal-title":"Thorac. Surg. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.201205-0913OC","article-title":"Spatial clusters of nontuberculous mycobacterial lung disease in the United States","volume":"186","author":"Adjemian","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1164\/rccm.201111-2016OC","article-title":"Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries","volume":"185","author":"Adjemian","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_10","first-page":"27","article-title":"Infection Sources of a Common Non-tuberculous Mycobacterial Pathogen, Mycobacterium avium Complex","volume":"4","author":"Nishiuchi","year":"2017","journal-title":"Front. Med. (Lausanne)"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"16393","DOI":"10.1073\/pnas.0908446106","article-title":"Opportunistic pathogens enriched in showerhead biofilms","volume":"106","author":"Feazel","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.3389\/fmicb.2017.02651","article-title":"Mycobacterium Biofilms","volume":"8","author":"Esteban","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.5588\/ijtld.14.0120","article-title":"The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: A systematic review","volume":"18","author":"Brode","year":"2014","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1164\/rccm.201002-0310OC","article-title":"Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems","volume":"182","author":"Prevots","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/infdis\/174.6.1212","article-title":"Protection from Mycobacterium avium complex disease in human immunodeficiency virus-infected persons with a history of tuberculosis","volume":"174","author":"Horsburgh","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gebert, M.J., Delgado-Baquerizo, M., Oliverio, A.M., Webster, T.M., Nichols, L.M., Honda, J.R., Chan, E.D., Adjemian, J., Dunn, R.R., and Fierer, N. (2018). Ecological Analyses of Mycobacteria in Showerhead Biofilms and Their Relevance to Human Health. MBio, 9.","DOI":"10.1128\/mBio.01614-18"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/519383","article-title":"The recovery of Mycobacterium avium-intracellulare complex (MAC) from the residential bathrooms of patients with pulmonary MAC","volume":"45","author":"Nishiuchi","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2166\/wh.2008.232","article-title":"Mycobacterium avium in a shower linked to pulmonary disease","volume":"6","author":"Falkinham","year":"2008","journal-title":"J. Water Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1126\/science.aaf8156","article-title":"Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium","volume":"354","author":"Bryant","year":"2016","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S2213-2600(15)00062-4","article-title":"Non-tuberculous mycobacteria in children: Muddying the waters of tuberculosis diagnosis","volume":"3","author":"Santiago","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/j.tube.2015.02.024","article-title":"The cell envelope of tubercle bacilli","volume":"95","author":"Daffe","year":"2015","journal-title":"Tuberculosis"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Vilcheze, C., and Kremer, L. (2017). Acid-Fast Positive and Acid-Fast Negative Mycobacterium tuberculosis: The Koch Paradox. Microbiol. Spectr., 5.","DOI":"10.1128\/microbiolspec.TBTB2-0003-2015"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1128\/IAI.67.7.3199-3206.1999","article-title":"Survival of Mycobacterium avium and Mycobacterium tuberculosis in acidified vacuoles of murine macrophages","volume":"67","author":"Gomes","year":"1999","journal-title":"Infect. Immun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1128\/iai.52.1.252-262.1986","article-title":"Evidence for inhibition of fusion of lysosomal and prelysosomal compartments with phagosomes in macrophages infected with pathogenic Mycobacterium avium","volume":"52","author":"Frehel","year":"1986","journal-title":"Infect. Immun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00281-013-0388-2","article-title":"Macrophages in tuberculosis: Friend or foe","volume":"35","author":"Guirado","year":"2013","journal-title":"Semin. Immunopathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1073\/pnas.0737613100","article-title":"Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest","volume":"100","author":"Fratti","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1385\/IR:35:3:179","article-title":"Pathogenesis of Mycobacterium avium infection: Typical responses to an atypical mycobacterium?","volume":"35","author":"Appelberg","year":"2006","journal-title":"Immunol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1099\/00221287-148-10-3155","article-title":"NRAMP1- or cytokine-induced bacteriostasis of Mycobacterium avium by mouse macrophages is independent of the respiratory burst","volume":"148","author":"Gomes","year":"2002","journal-title":"Microbiology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1189\/jlb.0206079","article-title":"Macrophage nutriprive antimicrobial mechanisms","volume":"79","author":"Appelberg","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.micpath.2010.12.004","article-title":"Mycobacterium avium uses apoptotic macrophages as tools for spreading","volume":"50","author":"Early","year":"2011","journal-title":"Microb. Pathog."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Thegerstrom, J., Jonsson, B., Brudin, L., Olsen, B., Wold, A.E., Ernerudh, J., and Friman, V. (2012). Mycobacterium avium subsp. avium and subsp. hominissuis give different cytokine responses after in vitro stimulation of human blood mononuclear cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0034391"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3389\/fimmu.2017.01633","article-title":"Type I Interferons in the Pathogenesis of Tuberculosis: Molecular Drivers and Immunological Consequences","volume":"8","author":"Donovan","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/S1473-3099(17)30623-0","article-title":"Genetics of human susceptibility to active and latent tuberculosis: Present knowledge and future perspectives","volume":"18","author":"Abel","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"a017848","DOI":"10.1101\/cshperspect.a017848","article-title":"Clinical Aspects of Adult Tuberculosis","volume":"6","author":"Loddenkemper","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/QCO.0b013e328055d9a2","article-title":"Therapy of nontuberculous mycobacterial disease","volume":"20","author":"Griffith","year":"2007","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/CMR.05030-11","article-title":"Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria","volume":"25","author":"Nash","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3201\/eid2507.181817","article-title":"Prescribing Patterns for Treatment of Mycobacterium avium Complex and M. xenopi Pulmonary Disease in Ontario, Canada, 2001\u20132013","volume":"25","author":"Brode","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1513\/AnnalsATS.201304-085OC","article-title":"Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease","volume":"11","author":"Adjemian","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1602109","DOI":"10.1183\/13993003.02109-2016","article-title":"Burden of non-tuberculous mycobacterial pulmonary disease in Germany","volume":"49","author":"Diel","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1601855","DOI":"10.1183\/13993003.01855-2016","article-title":"Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases","volume":"49","author":"Wagner","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"00109-2018","DOI":"10.1183\/23120541.00109-2018","article-title":"Hospital-based antibiotic use in patients with Mycobacterium avium complex","volume":"4","author":"Ricotta","year":"2018","journal-title":"ERJ Open Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0038-1660472","article-title":"Treatment of Mycobacterium avium Complex (MAC)","volume":"39","author":"Griffith","year":"2018","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ccm.2014.11.001","article-title":"Medications and monitoring in nontuberculous mycobacteria infections","volume":"36","author":"Egelund","year":"2015","journal-title":"Clin. Chest Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"TB Alliance (2008). Clarithromycin. Tuberculosis, 88, 92\u201395.","DOI":"10.1016\/S1472-9792(08)70005-2"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ccm.2014.10.005","article-title":"Treatment of slowly growing mycobacteria","volume":"36","author":"Philley","year":"2015","journal-title":"Clin. Chest Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/jac\/dku457","article-title":"Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents","volume":"70","author":"Lakshminarayana","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"Prideaux","year":"2015","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"TB Alliance (2008). Rifabutin. Tuberculosis, 88, 145\u2013147.","DOI":"10.1016\/S1472-9792(08)70022-2"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/17460441.2019.1629414","article-title":"Repositioning rifamycins for Mycobacterium abscessus lung disease","volume":"14","author":"Ganapathy","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e00155-17","DOI":"10.1128\/AAC.00155-17","article-title":"Rifabutin Is Active against Mycobacterium abscessus Complex","volume":"61","author":"Aziz","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/JCM.01612-13","article-title":"In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates","volume":"51","author":"Iakhiaeva","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thorsurg.2018.09.001","article-title":"Medical Management of Pulmonary Nontuberculous Mycobacterial Disease","volume":"29","author":"Philley","year":"2019","journal-title":"Thorac. Surg Clin."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(19)31882-3","article-title":"Management of drug-resistant tuberculosis","volume":"394","author":"Lange","year":"2019","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1473-3099(17)30418-8","article-title":"Multidrug therapy for leprosy: A game changer on the path to elimination","volume":"17","author":"Smith","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","article-title":"Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection","volume":"152","author":"Martiniano","year":"2017","journal-title":"Chest"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e02052-16","DOI":"10.1128\/AAC.02052-16","article-title":"Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease","volume":"61","author":"Yang","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1378\/chest.124.4.1482","article-title":"Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine","volume":"124","author":"Field","year":"2003","journal-title":"Chest"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1378\/chest.15-0543","article-title":"Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and\/or Rifampin","volume":"149","author":"Jarand","year":"2016","journal-title":"Chest"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/AAC.01505-12","article-title":"In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease","volume":"56","author":"Totten","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijantimicag.2009.12.008","article-title":"High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria","volume":"35","author":"Shen","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jac\/dky526","article-title":"A bedaquiline\/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria","volume":"74","author":"Ruth","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jmii.2017.05.001","article-title":"In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates","volume":"51","author":"Huang","year":"2018","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1749-6632.2011.05962.x","article-title":"Linezolid, the first oxazolidinone antibacterial agent","volume":"1222","author":"Leach","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1183\/09031936.00169114","article-title":"The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease","volume":"45","author":"Winthrop","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"520","DOI":"10.7883\/yoken.JJID.2014.498","article-title":"Evaluation of the Efficacy of Novel Oxazolidinone Analogues against Nontuberculous Mycobacteria In Vitro","volume":"68","author":"Zhao","year":"2015","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/JCM.00274-17","article-title":"In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria","volume":"55","author":"Wallace","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1128\/AAC.00763-06","article-title":"In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria","volume":"50","author":"Wallace","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e02752-16","DOI":"10.1128\/AAC.02752-16","article-title":"Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus","volume":"61","author":"Kim","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"i24","DOI":"10.1093\/jac\/dkx304","article-title":"Linezolid as treatment for pulmonary Mycobacterium avium disease","volume":"72","author":"Deshpande","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/AAC.45.3.764-767.2001","article-title":"Activities of linezolid against rapidly growing mycobacteria","volume":"45","author":"Wallace","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_73","first-page":"411","article-title":"Activities of Linezolid against nontuberculous mycobacteria","volume":"30","author":"Cavusoglu","year":"2007","journal-title":"New Microbiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1086\/322523","article-title":"Successful treatment of disseminated Mycobacterium chelonae infection with linezolid","volume":"33","author":"Wallace","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1365-2133.2004.06230.x","article-title":"Mycobacterium chelonae infection successfully treated with oral clarithromycin and linezolid","volume":"151","author":"Kyle","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"ref_76","first-page":"43","article-title":"Successful use of linezolid for refractory Mycobacterium abcessus infection: A case report","volume":"23","author":"Inoue","year":"2018","journal-title":"Respir. Med. Case Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jcrs.2019.03.001","article-title":"Successful management of severe post-LASIK Mycobacterium abscessus keratitis with topical amikacin and linezolid, flap ablation, and topical corticosteroids","volume":"45","author":"Bostan","year":"2019","journal-title":"J. Cataract. Refract. Surg."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4103\/0255-0857.90187","article-title":"Successfully treated Mycobacterium abscessus mastitis: A rare cause of breast masses","volume":"29","author":"Yasar","year":"2011","journal-title":"Indian J. Med. Microbiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"TB Alliance (2008). Tmc-207. Tuberculosis, 88, 168\u2013169.","DOI":"10.1016\/S1472-9792(08)70029-5"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1099\/jmm.0.001025","article-title":"In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria","volume":"68","author":"Martin","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Kim, D.H., Jhun, B.W., Moon, S.M., Kim, S.Y., Jeon, K., Kwon, O.J., Huh, H.J., Lee, N.Y., Shin, S.J., and Daley, C.L. (2019). In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00665-19"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1099\/jmm.0.000537","article-title":"In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria","volume":"66","author":"Cnockaert","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Li, B., Ye, M., Guo, Q., Zhang, Z., Yang, S., Ma, W., Yu, F., and Chu, H. (2018). Determination of MIC Distribution and Mechanisms of Decreased Susceptibility to Bedaquiline among Clinical Isolates of Mycobacterium abscessus. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.00175-18"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Pang, Y., Zheng, H., Tan, Y., Song, Y., and Zhao, Y. (2017). In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.02627-16"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Dupont, C., Viljoen, A., Thomas, S., Roquet-Baneres, F., Herrmann, J.L., Pethe, K., and Kremer, L. (2017). Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01225-17"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Brown-Elliott, B.A., and Wallace, R.J. (2019). In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.01919-18"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Brown-Elliott, B.A., Philley, J.V., Griffith, D.E., Thakkar, F., and Wallace, R.J. (2017). In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01798-16"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Yu, X., Gao, X., Li, C., Luo, J., Wen, S., Zhang, T., Ma, Y., Dong, L., Wang, F., and Huang, H. (2019). In Vitro Activities of Bedaquiline and Delamanid against Nontuberculous Mycobacteria Isolated in Beijing, China. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00031-19"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/infdis\/jit614","article-title":"In vivo evaluation of antibiotic activity against Mycobacterium abscessus","volume":"209","author":"Lerat","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1128\/AAC.00689-09","article-title":"ATP synthase inhibition of Mycobacterium avium is not bactericidal","volume":"53","author":"Lounis","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1128\/AAC.00459-15","article-title":"Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models","volume":"59","author":"Arnett","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1378\/chest.14-2764","article-title":"Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease","volume":"148","author":"Philley","year":"2015","journal-title":"Chest"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1128\/JCM.02087-16","article-title":"Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease","volume":"55","author":"Alexander","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Lindman, M., and Dick, T. (2019). Bedaquiline Eliminates Bactericidal Activity of beta-Lactams against Mycobacterium abscessus. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00827-19"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/jac\/dku504","article-title":"Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug","volume":"70","author":"Svensson","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.tube.2018.04.008","article-title":"Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)","volume":"111","author":"Liu","year":"2018","journal-title":"Tuberculosis"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1183\/13993003.01420-2016","article-title":"Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare?","volume":"48","author":"Krieger","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e02895-18","DOI":"10.1128\/mBio.02895-18","article-title":"Dual beta-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro","volume":"10","author":"Pandey","year":"2019","journal-title":"MBio"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e02613-18","DOI":"10.1128\/AAC.02613-18","article-title":"Select beta-Lactam Combinations Exhibit Synergy against Mycobacterium abscessus In Vitro","volume":"63","author":"Maggioncalda","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e00614-19","DOI":"10.1128\/AAC.00614-19","article-title":"Synergistic Efficacy of beta-Lactam Combinations against Mycobacterium abscessus Pulmonary Infection in Mice","volume":"63","author":"Maggioncalda","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e02623-18","DOI":"10.1128\/AAC.02623-18","article-title":"In Vitro Activity of the New beta-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with beta-Lactams against Mycobacterium abscessus Complex Clinical Isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2217\/fmb-2016-0234","article-title":"Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus","volume":"12","author":"Kaushik","year":"2017","journal-title":"Future Microbiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e02440-16","DOI":"10.1128\/AAC.02440-16","article-title":"Inhibition of the beta-Lactamase BlaMab by Avibactam Improves the In Vitro and In Vivo Efficacy of Imipenem against Mycobacterium abscessus","volume":"61","author":"Lefebvre","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/jac\/dku510","article-title":"beta-Lactamase inhibition by avibactam in Mycobacterium abscessus","volume":"70","author":"Dubee","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1128\/AAC.05080-14","article-title":"Impact of beta-lactamase inhibition on the activity of ceftaroline against Mycobacterium tuberculosis and Mycobacterium abscessus","volume":"59","author":"Dubee","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/jac\/dkw022","article-title":"Bactericidal and intracellular activity of beta-lactams against Mycobacterium abscessus","volume":"71","author":"Lefebvre","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Bentur, L., Gur, M., Ashkenazi, M., Livnat-Levanon, G., Mizrahi, M., Tal, A., Ghaffari, A., Geffen, Y., Aviram, M., and Efrati, O. (2019). Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection. J. Cyst. Fibros.","DOI":"10.1016\/j.jcf.2019.05.002"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/INF.0000000000001780","article-title":"Compassionate Nitric Oxide Adjuvant Treatment of Persistent Mycobacterium Infection in Cystic Fibrosis Patients","volume":"37","author":"Gur","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_111","first-page":"OA4950","article-title":"High Efficacy of High-dose Nitric Oxide and its Synergistic Effect with Antibiotics against Mycobacterium Abscessus","volume":"54","author":"Chau","year":"2019","journal-title":"Eur. Respirat. J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/mmi.13406","article-title":"A new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus","volume":"101","author":"Dupont","year":"2016","journal-title":"Mol. Microbiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1021\/acs.jmedchem.7b00582","article-title":"Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections","volume":"60","author":"Kozikowski","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1016\/j.bmc.2017.05.015","article-title":"Design, synthesis and evaluation of indole-2-carboxamides with pan anti-mycobacterial activity","volume":"25","author":"Franz","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e01503-18","DOI":"10.1128\/AAC.01503-18","article-title":"In Vitro Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria","volume":"62","author":"Rubio","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1128\/AAC.04347-14","article-title":"A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections","volume":"59","author":"Locher","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1128\/AAC.00743-12","article-title":"In vitro activity of TP-271 against Mycobacterium abscessus, Mycobacterium fortuitum, and Nocardia species","volume":"56","author":"Cynamon","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1021\/acsinfecdis.9b00172","article-title":"Cyclipostins and Cyclophostin Analogues as Multitarget Inhibitors That Impair Growth of Mycobacterium abscessus","volume":"5","author":"Madani","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ijantimicag.2017.12.001","article-title":"Cyclophostin and Cyclipostins analogues, new promising molecules to treat mycobacterial-related diseases","volume":"51","author":"Nguyen","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ejmech.2015.07.001","article-title":"Combating highly resistant emerging pathogen Mycobacterium abscessus and Mycobacterium tuberculosis with novel salicylanilide esters and carbamates","volume":"101","author":"Baranyai","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.bmc.2014.12.019","article-title":"Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates","volume":"23","author":"Kratky","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1093\/jac\/dkq372","article-title":"In vitro antimicrobial activities of capuramycin analogues against non-tuberculous mycobacteria","volume":"65","author":"Dubuisson","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1039\/C6OB00381H","article-title":"A biocatalytic approach to capuramycin analogues by exploiting a substrate permissive N-transacylase CapW","volume":"14","author":"Liu","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1128\/AAC.01603-09","article-title":"In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria","volume":"54","author":"Rendon","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1128\/AAC.00618-16","article-title":"Imidazo[1,2-a]Pyridine-3-Carboxamides Are Active Antimicrobial Agents against Mycobacterium avium Infection In Vivo","volume":"60","author":"Moraski","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/ijmy.ijmy_153_18","article-title":"Antimycobacterial strategies to evade antimicrobial resistance in the nontuberculous mycobacteria","volume":"8","author":"Millar","year":"2019","journal-title":"Int. J. Mycobacteriol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/jac\/dkr154","article-title":"Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae","volume":"66","author":"Chopra","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Marini, E., Di Giulio, M., Ginestra, G., Magi, G., Di Lodovico, S., Marino, A., Facinelli, B., Cellini, L., and Nostro, A. (2019). Efficacy of carvacrol against resistant rapidly growing mycobacteria in the planktonic and biofilm growth mode. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0219038"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Nowotarska, S.W., Nowotarski, K., Grant, I.R., Elliott, C.T., Friedman, M., and Situ, C. (2017). Mechanisms of Antimicrobial Action of Cinnamon and Oregano Oils, Cinnamaldehyde, Carvacrol, 2,5-Dihydroxybenzaldehyde, and 2-Hydroxy-5-Methoxybenzaldehyde against Mycobacterium avium subsp. paratuberculosis (Map). Foods, 6.","DOI":"10.3390\/foods6090072"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/jac\/dkz267","article-title":"Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus","volume":"74","author":"Bax","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_131","first-page":"e5112","article-title":"Utilizing the Promise of Omadacycline in a Resistant, Non-tubercular Mycobacterial Pulmonary Infection","volume":"11","author":"Minhas","year":"2019","journal-title":"Cureus"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Kaushik, A., Ammerman, N.C., Martins, O., Parrish, N.M., and Nuermberger, E.L. (2019). In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00470-19"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Shoen, C., Benaroch, D., Sklaney, M., and Cynamon, M. (2019). In Vitro Activities of Omadacycline against Rapidly Growing Mycobacteria. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.02522-18"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1128\/AAC.43.8.1870","article-title":"Mefloquine Is Active In Vitro and In Vivo against Mycobacterium avium Complex","volume":"43","author":"Bermudez","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1128\/AAC.00320-12","article-title":"Identification of (+)-erythro-mefloquine as an active enantiomer with greater efficacy than mefloquine against Mycobacterium avium infection in mice","volume":"56","author":"Bermudez","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1086\/375352","article-title":"Mefloquine, Moxifloxacin, and Ethambutol Are a Triple-Drug Alternative to Macrolide-Containing Regimens for Treatment of Mycobacterium avium Disease","volume":"187","author":"Bermudez","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/AAC.02985-15","article-title":"Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases","volume":"60","author":"Deshpande","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/jac\/dkx308","article-title":"A \u2018shock and awe\u2019 thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease","volume":"72","author":"Srivastava","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Boelaert, J.R., Appelberg, R., Gomes, M.S., Blasi, E., Mazzolla, R., Grosset, J., Lounis, N., Soteriadou, K., Thiakaki, M., and Taramelli, D. (2001). Experimental Results on Chloroquine and AIDS-Relataed Opportunistic Infections. J. Acquir. Immunodefic. Syndr., 300\u2013301.","DOI":"10.1097\/00042560-200103010-00017"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ejmech.2017.11.083","article-title":"Primaquine hybrids as promising antimycobacterial and antimalarial agents","volume":"143","author":"Pavic","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"11164","DOI":"10.1021\/cr500123g","article-title":"\u201cRecycling\u201d classical drugs for malaria","volume":"114","author":"Teixeira","year":"2014","journal-title":"Chem. Rev."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4269\/ajtmh.1963.12.121","article-title":"Pitfalls in a discovery: The chronicle of chloroquine","volume":"12","author":"Coatney","year":"1963","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ejmech.2008.08.011","article-title":"Primaquine revisited six decades after its discovery","volume":"44","author":"Vale","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tube.2009.07.002","article-title":"New anti-tuberculosis agents amongst known drugs","volume":"89","author":"Lougheed","year":"2009","journal-title":"Tuberculosis"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"56134","DOI":"10.1039\/C6RA10759A","article-title":"Primaquine-based ionic liquids as a novel class of antimalarial hits","volume":"6","author":"Ferraz","year":"2016","journal-title":"RSC Adv."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1016\/j.bmcl.2017.07.006","article-title":"Effects of novel triple-stage antimalarial ionic liquids on lipid membrane models","volume":"27","author":"Ferraz","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Ferraz, R., Teixeira, C., Gomes, P., and Prud\u00eancio, C. (2018). Chapter 16. Bioactivity of Ionic Liquids. Ionic Liquid Devices, The Royal Society of Chemistry.","DOI":"10.1039\/9781788011839-00404"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1039\/C3RA44286A","article-title":"Antibacterial activity of Ionic Liquids based on ampicillin against resistant bacteria","volume":"4","author":"Ferraz","year":"2014","journal-title":"RSC Adv."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Gomes, A., Ferraz, R., Ficker, L., Collins, M.S., Prudencio, C., Cushion, M.T., Teixeira, C., and Gomes, P. (2018). Chloroquine Analogues as Leads against Pneumocystis Lung Pathogens. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.00983-18"},{"key":"ref_150","unstructured":"Bento, C.M. (2019). Evaluation of the Effects of Selected Ionic Liquids against Mycobacterium avium. [Master\u2019s Thesis, University of Porto]."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tibtech.2011.05.001","article-title":"The expanding scope of antimicrobial peptide structures and their modes of action","volume":"29","author":"Nguyen","year":"2011","journal-title":"Trends Biotechnol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nri.2016.29","article-title":"The immunology of host defence peptides: Beyond antimicrobial activity","volume":"16","author":"Hancock","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Silva, T., and Gomes, M.S. (2017). Immuno-Stimulatory Peptides as a Potential Adjunct Therapy against Intra-Macrophagic Pathogens. Molecules, 22.","DOI":"10.3390\/molecules22081297"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1007\/s00253-017-8466-3","article-title":"Activity of human beta defensin-1 and its motif against active and dormant Mycobacterium tuberculosis","volume":"101","author":"Sharma","year":"2017","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.bbamem.2016.01.031","article-title":"Interaction between antimicrobial peptides and mycobacteria","volume":"1858","author":"Gutsmann","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.phrs.2017.10.011","article-title":"Antimicrobial peptides as an alternative to anti-tuberculosis drugs","volume":"128","author":"AlMatar","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.chom.2009.08.004","article-title":"Vitamin D3 induces autophagy in human monocytes\/macrophages via cathelicidin","volume":"6","author":"Yuk","year":"2009","journal-title":"Cell Host Microbe"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Rivas-Santiago, B., Castaneda-Delgado, J.E., Rivas Santiago, C.E., Waldbrook, M., Gonzalez-Curiel, I., Leon-Contreras, J.C., Enciso-Moreno, J.A., del Villar, V., Mendez-Ramos, J., and Hancock, R.E. (2013). Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and IDR-1018 to protect against Mycobacterium tuberculosis infections in animal models. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059119"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1128\/AAC.45.2.639-640.2001","article-title":"Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis","volume":"45","author":"Sharma","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1086\/424463","article-title":"Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy","volume":"190","author":"Kalita","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"653","DOI":"10.7164\/antibiotics.25.653","article-title":"Cryomycin, a new peptide antibiotic produced only at low temperature","volume":"25","author":"Yoshida","year":"1972","journal-title":"J. Antibiot."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1128\/AAC.04054-14","article-title":"The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo","volume":"59","author":"Gao","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.chembiol.2014.01.014","article-title":"Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2","volume":"21","author":"Gavrish","year":"2014","journal-title":"Chem. Biol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijantimicag.2010.03.029","article-title":"Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria","volume":"36","author":"Carroll","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4161\/bbug.1.6.13642","article-title":"Gene encoded antimicrobial peptides, a template for the design of novel anti-mycobacterial drugs","volume":"1","author":"Carroll","year":"2010","journal-title":"Bioeng. Bugs"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.3168\/jds.2018-16106","article-title":"The inhibitory effect of nisin on Mycobacterium avium ssp. paratuberculosis and its effect on mycobacterial cell wall","volume":"102","author":"Ali","year":"2019","journal-title":"J. Dairy Sci."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Cirone, K.M., Lahiri, P., Holani, R., Tan, Y.L., Arrazuria, R., De Buck, J., Barkema, H.W., and Cobo, E.R. (2019). Synthetic cathelicidin LL-37 reduces Mycobacterium avium subsp. paratuberculosis internalization and pro-inflammatory cytokines in macrophages. Cell Tissue Res.","DOI":"10.1007\/s00441-019-03098-4"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1128\/AAC.02475-12","article-title":"Cationic antimicrobial peptides and biogenic silver nanoparticles kill mycobacteria without eliciting DNA damage and cytotoxicity in mouse macrophages","volume":"57","author":"Mohanty","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1128\/iai.60.11.4720-4725.1992","article-title":"Activity of defensins from human neutrophilic granulocytes against Mycobacterium avium-Mycobacterium intracellulare","volume":"60","author":"Ogata","year":"1992","journal-title":"Infect. Immun."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1128\/AAC.02728-13","article-title":"Killing of Mycobacterium avium by lactoferricin peptides: Improved activity of arginine- and D-amino-acid-containing molecules","volume":"58","author":"Silva","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e00301-17","DOI":"10.1128\/mSphere.00301-17","article-title":"Lactoferricin Peptides Increase Macrophages\u2019 Capacity To Kill Mycobacterium avium","volume":"2","author":"Silva","year":"2017","journal-title":"mSphere"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cbpb.2011.09.003","article-title":"Cloning and localization of MCdef, a defensin from Manila clams (Ruditapes philippinarum)","volume":"161","author":"Adhya","year":"2012","journal-title":"Comp. Biochem. Physiol. B Biochem. Mol. Biol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fmicb.2017.00273","article-title":"Non-disulfide-Bridge Peptide 5.5 from the Scorpion Hadrurus gertschi Inhibits the Growth of Mycobacterium abscessus subsp. massiliense","volume":"8","author":"Trentini","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"das Neves, R.C., Trentini, M.M., de Castro e Silva, J., Simon, K.S., Bocca, A.L., Silva, L.P., Mortari, M.R., Kipnis, A., and Junqueira-Kipnis, A.P. (2016). Antimycobacterial Activity of a New Peptide Polydim-I Isolated from Neotropical Social Wasp Polybia dimorpha. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149729"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Marques-Neto, L.M., Trentini, M.M., das Neves, R.C., Resende, D.P., Procopio, V.O., da Costa, A.C., Kipnis, A., Mortari, M.R., Schwartz, E.F., and Junqueira-Kipnis, A.P. (2018). Antimicrobial and Chemotactic Activity of Scorpion-Derived Peptide, ToAP2, against Mycobacterium massiliensis. Toxins, 10.","DOI":"10.3390\/toxins10060219"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijantimicag.2016.11.013","article-title":"Evaluation of the antimicrobial activity of the mastoparan Polybia-MPII isolated from venom of the social wasp Pseudopolybia vespiceps testacea (Vespidae, Hymenoptera)","volume":"49","author":"Silva","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_177","first-page":"373","article-title":"Sur un microbe invisible antagoniste des bacilles dysent\u00e9riques","volume":"165","year":"1917","journal-title":"C. R. Acad. Sci."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.2147\/IDR.S218638","article-title":"Phage therapy as a renewed therapeutic approach to mycobacterial infections: A comprehensive review","volume":"12","author":"Azimi","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-981-13-7709-9_11","article-title":"Enzybiotics: Enzyme-Based Antibacterials as Therapeutics","volume":"1148","author":"Dams","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1517\/17425247.2015.1043125","article-title":"A first step toward liposome-mediated intracellular bacteriophage therapy","volume":"12","author":"Nieth","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"28701","DOI":"10.1038\/srep28701","article-title":"Mycobacteriophage SWU1 gp39 can potentiate multiple antibiotics against Mycobacterium via altering the cell wall permeability","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/343812","article-title":"Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: A model for phage therapy of intracellular bacterial pathogens","volume":"186","author":"Broxmeyer","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/mdr.2006.12.1","article-title":"In vivo efficacy of phage therapy for Mycobacterium avium infection as delivered by a nonvirulent mycobacterium","volume":"12","author":"Danelishvili","year":"2006","journal-title":"Microb. Drug Resist."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2958.2009.06775.x","article-title":"Mycobacteriophage Lysin B is a novel mycolylarabinogalactan esterase","volume":"73","author":"Payne","year":"2009","journal-title":"Mol. Microbiol."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Catalao, M.J., Milho, C., Gil, F., Moniz-Pereira, J., and Pimentel, M. (2011). A second endolysin gene is fully embedded in-frame with the lysA gene of mycobacteriophage Ms6. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020515"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.enzmictec.2014.04.018","article-title":"Growth inhibition of Mycobacterium smegmatis by mycobacteriophage-derived enzymes","volume":"63","author":"Grover","year":"2014","journal-title":"Enzyme Microb. Technol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"19277","DOI":"10.3390\/molecules201019277","article-title":"Antimycobacterial Activities of Endolysins Derived From a Mycobacteriophage, BTCU-1","volume":"20","author":"Lai","year":"2015","journal-title":"Molecules"},{"key":"ref_188","first-page":"96","article-title":"Iron in intracellular infection: To provide or to deprive?","volume":"3","author":"Appelberg","year":"2013","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1128\/JB.00359-16","article-title":"Iron Homeostasis in Mycobacterium tuberculosis: Mechanistic Insights into Siderophore-Mediated Iron Uptake","volume":"198","author":"Sritharan","year":"2016","journal-title":"J. Bacteriol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1128\/JB.01312-10","article-title":"Mycobacterium tuberculosis can utilize heme as an iron source","volume":"193","author":"Jones","year":"2011","journal-title":"J. Bacteriol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1073\/pnas.1009516108","article-title":"Discovery and characterization of a unique mycobacterial heme acquisition system","volume":"108","author":"Tullius","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"10101","DOI":"10.1074\/jbc.M112.448399","article-title":"A new way to degrade heme: The Mycobacterium tuberculosis enzyme MhuD catalyzes heme degradation without generating CO","volume":"288","author":"Nambu","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1091\/mbc.e02-12-0780","article-title":"Mycobacterium\u2019s arrest of phagosome maturation in macrophages requires Rab5 activity and accessibility to iron","volume":"14","author":"Kelley","year":"2003","journal-title":"Mol. Biol. Cell"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2958.2007.05935.x","article-title":"The role of iron in Mycobacterium smegmatis biofilm formation: The exochelin siderophore is essential in limiting iron conditions for biofilm formation but not for planktonic growth","volume":"66","author":"Ojha","year":"2007","journal-title":"Mol. Microbiol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/mmi.13734","article-title":"Defining a temporal order of genetic requirements for development of mycobacterial biofilms","volume":"105","author":"Yang","year":"2017","journal-title":"Mol. Microbiol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1073\/pnas.97.3.1252","article-title":"The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages","volume":"97","author":"Rutter","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/infdis\/jit250","article-title":"Disruption of mycobactin biosynthesis leads to attenuation of Mycobacterium tuberculosis for growth and virulence","volume":"208","author":"Reddy","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Gomes, A.C., Moreira, A.C., Mesquita, G., and Gomes, M.S. (2018). Modulation of Iron Metabolism in Response to Infection: Twists for All Tastes. Pharmaceuticals, 11.","DOI":"10.3390\/ph11030084"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1054\/tuld.1999.0216","article-title":"Effects of iron deprivation on Mycobacterium avium growth","volume":"79","author":"Gomes","year":"1999","journal-title":"Tuber Lung Dis."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.micinf.2010.01.003","article-title":"Identification of a new hexadentate iron chelator capable of restricting the intramacrophagic growth of Mycobacterium avium","volume":"12","author":"Fernandes","year":"2010","journal-title":"Microbes Infect."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jinorgbio.2017.07.017","article-title":"The influence of functional groups on the permeation and distribution of antimycobacterial rhodamine chelators","volume":"175","author":"Moniz","year":"2017","journal-title":"J. Inorg. Biochem."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jinorgbio.2013.01.002","article-title":"Rhodamine labeling of 3-hydroxy-4-pyridinone iron chelators is an important contribution to target Mycobacterium avium infection","volume":"121","author":"Moniz","year":"2013","journal-title":"J. Inorg. Biochem."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1039\/C5MD00456J","article-title":"Antimycobacterial activity of rhodamine 3,4-HPO iron chelators against Mycobacterium avium: Analysis of the contribution of functional groups and of chelator\u2019s combination with ethambutol","volume":"6","author":"Moniz","year":"2015","journal-title":"MedChemComm"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"8610","DOI":"10.1038\/srep08610","article-title":"ATP exhibits antimicrobial action by inhibiting bacterial utilization of ferric ions","volume":"5","author":"Tatano","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1128\/AAC.05114-14","article-title":"A novel antimycobacterial compound acts as an intracellular iron chelator","volume":"59","author":"Dragset","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Torfs, E., Piller, T., Cos, P., and Cappoen, D. (2019). Opportunities for Overcoming Mycobacterium tuberculosis Drug Resistance: Emerging Mycobacterial Targets and Host-Directed Therapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20122868"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Silva, R.A., Pais, T.F., and Appelberg, R. (1998). Evaluation of IL-12 in Immunotherapy and Vaccine Design in Experimental Mycobacterium avium Infections. J. Immunol., 5578\u20135585.","DOI":"10.4049\/jimmunol.161.10.5578"},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Kim, S.H., Cho, D., and Kim, T.S. (2001). Induction of in vivo resistance to Mycobacterium avium infection by intramuscular injection with DNA encoding interleukin-18. Immunology, 234\u2013241.","DOI":"10.1046\/j.1365-2567.2001.01150.x"},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Skerry, C., Harper, J., Klunk, M., Bishai, W.R., and Jain, S.K. (2012). Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039680"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3201\/eid1510.090310","article-title":"Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy","volume":"15","author":"Winthrop","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1183\/09031936.00063514","article-title":"Mycobacterial diseases developed during anti-tumour necrosis factor-alpha therapy","volume":"44","author":"Yoo","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.smim.2014.04.003","article-title":"Tumor necrosis factor alpha in mycobacterial infection","volume":"26","author":"Dorhoi","year":"2014","journal-title":"Semin. Immunol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1128\/IAI.01011-07","article-title":"Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs","volume":"76","author":"Chakravarty","year":"2008","journal-title":"Infect. Immun."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"42004","DOI":"10.1038\/srep42004","article-title":"Attenuation of lymphocyte immune responses during Mycobacterium avium complex-induced lung disease due to increasing expression of programmed death-1 on lymphocytes","volume":"7","author":"Shu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: The unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Zullo, A.J., Jurcic Smith, K.L., and Lee, S. (2014). Mammalian target of Rapamycin inhibition and mycobacterial survival are uncoupled in murine macrophages. BMC Biochem., 15.","DOI":"10.1186\/1471-2091-15-4"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1101\/gad.1599207","article-title":"Autophagy: Process and function","volume":"21","author":"Mizushima","year":"2007","journal-title":"Genes Dev."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"12668","DOI":"10.1074\/jbc.M111.320135","article-title":"Mycobacterial induction of autophagy varies by species and occurs independently of mammalian target of rapamycin inhibition","volume":"287","author":"Zullo","year":"2012","journal-title":"J. Biol. Chem."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/1\/18\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:18:50Z","timestamp":1760361530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/1\/18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":219,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["antibiotics9010018"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics9010018","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,3]]}}}